Search

Johnson and Johnson

Closed

SectorHealthcare

271.04 0.13

Overview

Share price change

24h

Current

Min

270.29

Max

271.92

Key metrics

By Trading Economics

Income

299M

5.5B

Sales

1.2B

25B

P/E

Sector Avg

31.297

55.725

EPS

2.9

Dividend yield

1.94

Profit margin

21.865

Employees

138,200

EBITDA

721M

9B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+5.67% upside

Dividends

By Acuity

Dividend yield

Sector Avg

1.94%

2.25%

Next Earnings

13 Oct 2026

Next Dividend date

8 Dec 2026

Next Ex Dividend date

24 Nov 2026

Market Stats

By TradingEconomics

Market Cap

31B

649B

Previous open

270.91

Previous close

271.04

News Sentiment

By Acuity

74%

26%

283 / 339 Healthcare

Johnson and Johnson Chart

Past performance is not a reliable indicator of future results.

Related News

26 Sept 2026, 00:01 UTC

Event

Johnson & Johnson's TREMFYA® met endpoints in the Phase 4 STAR study, but the stock is trading lower in after-market hours amid routine fluctuations.

25 Sept 2026, 20:07 UTC

Event
News

Johnson & Johnson's stock rose after positive Phase 4 STAR study results for Tremfya and encouraging long-term data for CARVYKTI in multiple myeloma patients.

24 Sept 2026, 23:01 UTC

Johnson & Johnson's shares are advancing in after-market trading, holding a roughly flat position since Thursday's close amid limited fluctuations.

23 Sept 2026, 23:05 UTC

Johnson & Johnson is experiencing a slight decline in after-market trading, reflecting a cumulative return near the lower end of its one-month trading range.

22 Sept 2026, 20:07 UTC

Event
Social Media

Johnson & Johnson shares fell following a slight decline from Monday's close, despite bullish social media sentiment and positive Phase 3 study results for CAPLYTA®.

21 Sept 2026, 20:06 UTC

Social Media
Event
News

Johnson & Johnson's stock is declining today despite receiving EU approval for ICOTYDE, a new treatment for plaque psoriasis, and positive Phase 3 results for Caplyta.

18 Sept 2026, 23:01 UTC

Johnson & Johnson's shares advanced modestly in after-market trading, continuing positive momentum following five consecutive sessions that ended higher.

17 Sept 2026, 23:06 UTC

Johnson & Johnson is trading slightly higher in after-market hours, continuing a trend of five consecutive sessions finishing higher since Thursday's close.

16 Sept 2026, 23:06 UTC

Johnson & Johnson's shares are trading lower in after-market hours, briefly dipping to a low while remaining below their 20-day moving average.

15 Sept 2026, 23:01 UTC

Johnson & Johnson shares are lower in after-market trading amid negative market sentiment following a sharp decline in the New York Empire State Manufacturing Index.

14 Sept 2026, 23:06 UTC

Event

Johnson & Johnson shares rose in after-market trading following the final survival analysis results of the Phase 3 PAPILLON study for RYBREVANT and chemotherapy.

12 Sept 2026, 00:01 UTC

News
Social Media

Johnson & Johnson shares rose in after-hours trading amid reports of Apollo Global Management discussing a $20 billion acquisition of its DePuy Synthes unit.

11 Sept 2026, 23:41 UTC

News
Social Media

Johnson & Johnson shares higher after news of Apollo Global Management's interest in acquiring its $20 billion orthopedics unit, DePuy Synthes.

10 Sept 2026, 20:07 UTC

Social Media
News

Johnson & Johnson shares are lower despite receiving CE Marking for its ACUVUE OASYS MAX 2-Week lens, with HSBC raising its price target to $320.

9 Sept 2026, 23:01 UTC

Johnson & Johnson shares are higher in after-market trading, reflecting a modest increase since Wednesday's close despite three consecutive sessions of declines.

8 Sept 2026, 20:02 UTC

Social Media

Johnson & Johnson shares are lower today amid declines in the Pharmaceuticals sub-sector, despite strong merger and acquisition capacity estimated at $80 billion.

5 Sept 2026, 00:01 UTC

Johnson & Johnson shares are higher in after-market trading, with no specific news driving the move. The stock reached a session high earlier today.

4 Sept 2026, 20:08 UTC

News

Shares of Johnson & Johnson are lower as Timothy Schmid exercised stock options for 33,597 shares valued at approximately $4.39 million.

3 Sept 2026, 23:41 UTC

News

Johnson & Johnson's shares are lower in after-market trading following FDA approval of IMAAVY and a jury verdict in a talc case.

2 Sept 2026, 23:06 UTC

News

Johnson & Johnson will participate in the Deutsche Bank 2026 Healthcare Summit on September 17. Shares are higher in after-market trading following the announcement.

1 Sept 2026, 20:01 UTC

Johnson & Johnson shares are higher today, reaching the upper end of their one-month trading range during the session. No specific news was identified.

31 Aug 2026, 23:06 UTC

News

Johnson & Johnson shares are higher in after-market trading following the announcement of an investor conference call on October 13, 2026, for third-quarter results.

29 Aug 2026, 00:01 UTC

News

Johnson & Johnson shares higher in after-market trading following FDA approval of Stelara for pediatric ulcerative colitis treatment, expanding its market potential.

28 Aug 2026, 20:08 UTC

Johnson & Johnson shares are higher during Friday's session, reflecting a modest gain since Thursday's close amid routine trading and rising Treasury yields.

27 Aug 2026, 23:01 UTC

Johnson & Johnson shares advanced in after-market trading, recovering from earlier volatility. Broader market context includes a decline in initial jobless claims.

26 Aug 2026, 23:06 UTC

Johnson & Johnson shares are lower during after-market hours, reflecting a decline since Wednesday's close amid broader market concerns over persistent inflation pressures.

25 Aug 2026, 23:06 UTC

Johnson & Johnson shares are lower in after-market trading, reflecting broader market trends and a decline in crude oil prices influencing investor sentiment.

24 Aug 2026, 19:06 UTC

Social Media
News

Johnson & Johnson's shares are higher today, recovering from earlier volatility and trading above its 20-day moving average near a one-month peak.

21 Aug 2026, 23:06 UTC

Johnson & Johnson shares are higher in after-hours trading, maintaining a position above the 20-day moving average despite a slight pullback from earlier gains.

20 Aug 2026, 23:41 UTC

News

Johnson & Johnson shares are higher in after-market trading following operational sales growth and a raised full-year outlook amid recent FDA clearances for its bronchoscopy software.

Peer Comparison

Price change

Johnson and Johnson Forecast

Price Target

By TipRanks

5.67% upside

12 Months Forecast

Average 286.611 USD  5.67%

High 320 USD

Low 260 USD

Based on 18 Wall Street analysts offering 12 month price targets forJohnson and Johnson - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

18 ratings

14

Buy

4

Hold

0

Sell

Sentiment

By Acuity

283 / 339 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.